Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial
Background: Dupuytren's disease is a common fibrotic condition of the hand that causes irreversible flexion contractures of the fingers, with no approved therapy for early stage disease. Our previous analysis of surgically-excised tissue defined tumour necrosis factor (TNF) as a potential thera...
Main Authors: | Jagdeep Nanchahal, Catherine Ball, Dominique Davidson, Lynn Williams, William Sones, Fiona E. McCann, Marisa Cabrita, Jennifer Swettenham, Neil J. Cahoon, Bethan Copsey, E. Anne Francis, Peter C. Taylor, Joanna Black, Vicki S. Barber, Susan Dutton, Marc Feldmann, Sarah E. Lamb |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-07-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396418302299 |
Similar Items
-
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. [version 2; referees: 2 approved]
by: Jagdeep Nanchahal, et al.
Published: (2017-11-01) -
Recent advances in the understanding of Dupuytren’s disease [version 1; referees: 3 approved]
by: Thomas Layton, et al.
Published: (2019-02-01) -
What do we know about managing Dupuytren’s disease cost-effectively?
by: Melina Dritsaki, et al.
Published: (2018-01-01) -
Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) [version 2; referees: 2 approved]
by: May Ee Png, et al.
Published: (2019-02-01) -
Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) [version 1; referees: 2 approved]
by: May Ee Png, et al.
Published: (2018-12-01)